You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: February 22, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for MLN0128

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug MLN0128?

MLN0128 is an investigational drug.

There have been 36 clinical trials for MLN0128. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2015.

The most common disease conditions in clinical trials are Neoplasms, Carcinoma, and Breast Neoplasms. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), and M.D. Anderson Cancer Center.

There are twenty-nine US patents protecting this investigational drug and two hundred and sixty-two international patents.

Recent Clinical Trials for MLN0128
Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)National Cancer Institute (NCI)Phase 2
Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)Southwest Oncology GroupPhase 2
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung CancerNational Cancer Institute (NCI)Phase 1

See all MLN0128 clinical trials

Clinical Trial Summary for MLN0128

Top disease conditions for MLN0128
Top clinical trial sponsors for MLN0128

See all MLN0128 clinical trials

US Patents for MLN0128

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MLN0128   Start Trial Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH)   Start Trial
MLN0128   Start Trial Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases ZHEJIANG DTRM BIOPHARMA CO. LTD. (Hangzhou, CN)   Start Trial
MLN0128   Start Trial Combination pharmaceutical compositions and uses thereof INTELLIKINE LLC (La Jolla, CA)   Start Trial
MLN0128   Start Trial Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MLN0128

Drugname Country Document Number Estimated Expiration Related US Patent
MLN0128 Australia 2014348657 2033-11-13   Start Trial
MLN0128 Australia 2017245411 2033-11-13   Start Trial
MLN0128 Canada 2929181 2033-11-13   Start Trial
MLN0128 China 105899232 2033-11-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.